AKT1 and prostate cancer: Although one independent study has demonstrated the anti-tumor activity of MIR493 in prostate cancer via upregulation of N6-methyladenosine levels [251], another study revealed that MIR493 stimulates AKT signaling to enhance prostate cancer proliferation [252].